Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer.
Sánchez-Muñoz
Alfonso
A
García-Tapiador
Ana Maria
AM
Dueñas-García
Rosario
R
Jaén-Morago
Ana
A
Ortega-Granados
Ana Laura
AL
Martínez-Ortega
Esther
E
Fernández Morales
Margarita
M
Fernández-Navarro
Mónica
M
de la Torre Cabrera
Capilla
C
Dueñas
Basilio
B
Ureña
Crisostomo
C
Martínez
Julia
J
Morales
Francisco
F
Ramírez-Tortosa
César
C
Sánchez-Rovira
Pedro
P
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D015331:Cohort Studies; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D018734:Genes, erbB-2; D006801:Humans; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D016019:Survival Analysis; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab